NCT07356050 Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease
| NCT ID | NCT07356050 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Children's Hospital Medical Center, Cincinnati |
| Condition | Sickle Cell Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 130 participants |
| Start Date | 2025-03-13 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 130 participants in total. It began in 2025-03-13 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to learn if infants with sickle cell disease (SCD) develop adequate protection after measles vaccines. (not looking at any prolonged duration)
Eligibility Criteria
Inclusion Criteria: 1. Participants with confirmed Sickle Cell Disease. 2. Participants 6 months and 6 years of age and due for measles vaccination within 3 months per national guidelines. 3. Willing and able to provide informed consent 4. Ability to comply with study related evaluations and follow-up visits. Exclusion Criteria: 1\. Known primary immunodeficiency syndrome, cancer, or acquired immunodeficiency syndrome (AIDS) that would preclude vaccination with live virus vaccines.
Contact & Investigator
Alexandra Power-Hays, MD
PRINCIPAL INVESTIGATOR
Children's Hospital Medical Center, Cincinnati
Frequently Asked Questions
Who can join the NCT07356050 clinical trial?
This trial is open to participants of all sexes, aged 6 Months or older, up to 6 Years, studying Sickle Cell Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07356050 currently recruiting?
Yes, NCT07356050 is actively recruiting participants. Contact the research team at Teresa.Latham@cchmc.org for enrollment information.
Where is the NCT07356050 trial being conducted?
This trial is being conducted at Cincinnati, United States, Accra, Ghana, Mwanza, Tanzania.
Who is sponsoring the NCT07356050 clinical trial?
NCT07356050 is sponsored by Children's Hospital Medical Center, Cincinnati. The principal investigator is Alexandra Power-Hays, MD at Children's Hospital Medical Center, Cincinnati. The trial plans to enroll 130 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.